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Abstract Hormonal male contraception clinical trials began in
the 1970s. The method is based on the use of exogenous testos-
terone alone or in combination with a progestin to suppress the
endogenous production of testosterone and spermatogenesis.
Studies using testosterone alone showed that the method was
very effective with few adverse effects. Addition of a progestin
increases the rate and extent of suppression of spermatogenesis.
Common adverse effects include acne, injection site pain, mood
change including depression, and changes in libido that are usu-
allymild and rarely lead to discontinuation. Current development
includes long-acting injectables and transdermal gels and novel
androgens that may have both androgenic and progestational
activities. Surveys showed that over 50 % of men will accept a
new male method and female partners will trust their partner to
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Introduction
Despite improvement in modern female contraceptive
methods and the ability to rapidly introduce new effective
methods to developing countries, there are unmet needs for
family planning in women 15 to 49 years [1–3]. Achieving the
desired number of children is beneficial to women, families,
and society. In order to meet the unmet need for women,
countries need to make available modern contraceptives, pro-
vide high quality services, and improve access to such ser-
vices. In addition, development of new methods of contracep-
tion involving men should be a priority. Male contraceptive
methods available to the public include the condomwhich has
a high user failure rate [4] and vasectomy which is considered
irreversible and involves a minor surgical procedure.
The mechanisms of action of hormonal male contraception
is based on the suppression of the secretion and production of
the gonadotropins, both luteinizing and follicle stimulating
hormone (LH, FSH), from the pituitary by exogenous sex
steroids (androgens with or without progestins) or gonadotro-
pin releasing hormone (GnRH) analogues. Gonadotropin sup-
pression results in marked decrease in intratesticular testoster-
one and suppression of spermatogenesis. This profound sup-
pression of sperm output inhibits fertility in men providing an
effective male-directed contraceptive method. Sexual func-
tion, male characteristics, and effects on nonreproductive or-
gans are maintained by the androgen (usually testosterone)
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nongovernment agencies, academia, and industry may generate
adequate interest and collaboration to develop and market the
first male hormonal contraception.
take oral Bmale pills.^ Partnership between government,
that is part of the contraceptive regimen. The current goal is to
identify a hormonal male contraceptive that is effective, re-
versible, safe, acceptable, affordable, and available. The focus
has been on the development of a long-acting hormonal de-
livery system such as testosterone undecanoate intramuscular
injections (IM) or user-friendly provider-independent combi-
nations of androgens and progestins such as transdermal ap-
plications of combined testosterone and nestorone gels or nov-
el androgens that have activity of both hormones [5–8].
Early Studies Demonstrating Efficacy of Hormonal
Male Contraception (Table 1)
Beginning in the early 1970s, the National Institutes of Health
(NIH) in the USA began male hormonal contraceptive clinical
trials using testosterone enanthate, an intramuscular (IM) in-
jectable preparation available in many countries since the
1950s with good safety profile. These early studies showed
when small numbers of healthy male volunteers were admin-
istered testosterone enanthate IM for several months, sperm
concentration was markedly suppressed to very low levels
(oligozoospermia, low sperm concentration arbitrarily defined
as <5 or <3 million/ml in studies in the 1990s and <1 million/
ml in more recent studies, and azoospermia, no sperm cells in
ejaculate) in a high proportion of men [9–12]. The World
Health Organization (WHO) undertook two multicenter, mul-
tinational studies involving larger numbers of healthy men in
the 1990s that established the efficacy of male hormonal con-
traception when sperm output was suppressed to very low
levels. The first study recruited 271 healthy couples from ten
centers in seven countries in four continents [13]. Testosterone
enanthate was administered IM every week for ≤6 months
until the men achieved azoospermia (Table 1). After azoosper-
mia was reached, 157 couples used the weekly testosterone
enanthate injections as their only method of contraception,
and 119 couples completed the efficacy of 12 months. There
was one pregnancy in 1486 months of efficacy evaluation
(Pearl Index 0.8 [95 % confidence interval (CI) 0.02–4.5]
per 100 person-years; Pearl Index is the most common mea-
sure of the effectiveness of contraceptive methods and is based
on the number of pregnancies, the number of women, and
time exposed to the method) [13]. The second study followed
using the same study design except the couples were eligible
for entry into the efficacy phase when the male partner devel-
oped severe oligozoospermia (initially arbitrarily defined as
<5 million/ml ejaculate, later revised as <3 million/ml). The
study recruited 399 couples from three countries in Asia, and
six countries in Australia, Europe, and North America. Three
hundred and fifty-seven men (89 %) completed the efficacy
phase with eight men (2.2 %) failing to reach the threshold for
oligozoospermia (Table 1). After 180 person-years of expo-
sure, five pregnancies occurred with three occurring when
sperm concentration was >4 million/ml, and the threshold
criteria for entry into efficacy phase was lowered to <3 mil-
lion/ml. No pregnancy occurred in the azoospermic group,
and four occurred in the oligozoospermic group. The overall
pregnancy rate was 1.4 (95 % CI 0.4 to 3.7) per 100 person-
years. In these two studies, the azoospermia rate was higher in
Asian men, with non-Asian less likely to achieve suppression
to severe oligozoospermia. The study also demonstrated that
the pregnancy rate in the couples in the efficacy phase was
related to the sperm output of the male partner. These two
early landmark studies provided strong evidence that when
spermatogenesis is suppressed to yield very low sperm output
by the administration of exogenous androgens, contraceptive
efficacy can be as high as female contraceptive methods [14].
These two large-scale studies were confirmed by a smaller
contraceptive efficacy study using testosterone implants. In
the first single center study, the investigators implanted 800-
or 1200-mg testosterone implants into the abdominal wall
with or without a 5-alpha-reductase inhibitor to suppress
intratesticular dihydrotestosterone levels. The rationale of
adding a 5-alpha-reductase inhibitor was to completely sup-
press the conversion of testosterone to the active androgen
dihydrotestosterone in the testis and more effective suppres-
sion of spermatogenesis. When the sperm concentration
reached <1million/ml in the male partner, the 16 couples were
allowed to enter the efficacy phase with 16. No pregnancy
occurred during 214 months of exposure [15].
Development of Androgens, Progestins, and GnRH
Antagonists as Potential Male Contraceptives
Studies that followed examined adding progestins and GnRH
analogues to the androgen (testosterone) to increase the rate of
suppression of spermatogenesis to severe oligozoospermia to
over 90 % in men. Proges t ins inc lud ing depo t
medroxyprogesterone acetate, levonorgestrel pills and im-
plants, desogestrel pills, etonogestrel implants, oral cyproter-
one acetate pills, and norethindrone enanthate injectables have
been used in combination with testosterone implants, inject-
ables, and transdermal preparations. These small contracep-
tive clinical trials showed that addition of a progestin in-
creased the proportion of men whose spermatogenesis was
suppressed to produce very low sperm output (<1 million/
ml) [16–18]. A two-center study employed a combination of
testosterone implants 800 mg every 4 months together with
depot medroxyprogesterone acetate 300 mg IM every
3 months. Efficacy phase of the study began when the male
partner had two consecutive monthly semen samples with
sperm concentration <1 million/ml. Fifty-five couples en-
rolled in the study, and 51 couples entered the efficacy phase.
There was no pregnancy reported during the 425 months of
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exposure. The contraceptive failure rate was zero (95 % CI 0
to 8) per 100 person-years (Table 1) [19].
GnRH agonists downregulate gonadotropin receptor ac-
tions that result in initial elevation but subsequent marked
suppression of the gonadotropins. GnRH antagonists act by
competitive binding to receptors and reduced both LH and
FSH to very low levels. GnRH agonists were not effective
suppressors of sperm output [20, 21], whereas the antagonists
were very effective. Unfortunately, clinical studies showed
that GnRH antagonists required frequent subcutaneous injec-
tions and were expensive to produce. Some of the antagonists
caused a histamine-like acute reaction on the skin [22, 23].
Subsequent short-term studies showed that the suppression of
spermatogenesis by GnRH antagonists plus an androgen can
be maintained by administration of the androgen alone [24,
25]. Because GnRH antagonists required frequent injections,
orally bioavailable GnRH antagonists are being developed but
not yet available for testing as a contraceptive agent.
More Recent Contraceptive Efficacy Trials
with Injectable Testosterone Undecanoate
and Norethisterone Enanthate (Table 1)
New testosterone delivery systems have been developed for
testosterone replacement in hypogonadal men. Testosterone
undecanoate administered as IM injection was studied as a
potential long-acting hormonal male contraceptive agent
[26]. Chinese investigators studied spermatogenic suppres-
sion by testosterone undecanoate administered as a monthly
injection to 308 volunteers. During a 6-month suppression
phase, 9 out of 308 men did not reach a sperm concentration
of <3 million/ml (failure of suppression 2.9 %) and 296 men
entered the efficacy phase of 6 months. There were no preg-
nancies when the men had azoospermia or severe oligozoos-
permia. Sperm rebound to levels above threshold during treat-
ment occurred in 2.3 %, and one pregnancy occurred during
sperm rebound [27]. Based on these encouraging results, these
investigators conducted a phase 3 mutlicenter contraceptive
efficacy study in 1045 men in ten centers in China.
Testosterone undecanoate 500 mg was administered as a
monthly injection after an initial loading dose of testosterone
undecanoate 1000 mg. During the suppression phase of
6 months, 43/898 participants (4.8 %) did not reach sperm
concentration of <1 million/ml. Eight hundred fifty-five cou-
ples entered efficacy phase of 24 months, and 733 completed
the study. During treatment period, 1.3 % of subjects had a
sperm rebound during treatment. During the efficacy phase,
nine pregnancies occurred of which six might have been due
to sperm rebound. There were 1554 months of exposure, and
the failure rates were 1.0 % (95 % CI 0.3 to 1.7 %) and 1.1
(95 % CI 0.4 to1.8) at the end of 12 and 24 months, respec-
tively. The study provided substantial evidence that
testosterone undecanoate alone may provide a safe, effective,
reversible contraceptive formulation for Asian men [28••].
Because of the finding in non-Asian men that the suppres-
sion of spermatogenesis may not be as efficacious using an-
drogen alone, the World Health Organization (WHO) together
with the Contraceptive Research and Development Program
(CONRAD) at Eastern Virginia Medical School led a multi-
center, multinational study that recruited 320 men who were
given a combination of testosterone undecanoate (1000 mg)
and a progestin norethisterone enanthate (200 mg) every
8 weeks with a suppression phase of up to 6 months and an
efficacy phase (no other method of contraception for the cou-
ple) for 12 months. These 320 participants received at least
one injection, and 95.9 % reached the efficacy eligibility of
sperm concentration <1 million/ml. Four pregnancies oc-
curred in 266 couples participating in the study during the
efficacy phase giving a contraceptive failure rate of 1.5
(95%CI 0.59 to 4.14 ) per 100 users. Common adverse events
included acne, pain at injection site, and mood changes which
led to the WHO Human Reproduction Program Research
Project Review Panel to recommend halting further injections
before the planned end of study. Despite the early termination,
this study provided additional evidence that an androgen plus
a progestin achieved suppression of spermatogenesis to very
low levels in over 95 % of men and a failure rate of 1.5 %
consistent with the results of the early studies [29•]
Reported Adverse Events from Male Hormonal
Contraception Clinical Trials (Table 2)
Testosterone and its esters are used as replacement therapy
for hypogonadal men, and their side effects are well-known
[30–32]. The common side effects are acne, oiliness of skin,
weight gain, decrease in high-density lipoprotein (HDL) cho-
lesterol, increases in hematocrit and hemoglobin, and sleep-
related breathing disorders. These adverse effects may be de-
pendent on the dose and methods of testosterone administra-
tion. The potential long-term effects on the prostate are not
known. It is unlikely that testosterone replacement causes be-
nign prostatic hyperplasia or prostate cancer [32]. Because of
the standard of care requiring monitoring of testosterone treat-
ment with digital rectal examination and serum prostate-
specific antigen concentrations in many clinical trials, this
may result in more prostate biopsies [32]. Recent controversy
on testosterone therapy and cardiovascular disease stemmed
from controversial epidemiological studies [33–35] and meta-
analyses [36, 37] where some of the studies showed that tes-
tosterone therapy may be associated with increases in cardio-
vascular disease risk including myocardial infarction and
stroke and others demonstrated opposite results. The United
States Food and Drug Administration and many experts in the
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field have expressed their opinion that the evidence for or
against cardiovascular risk is inadequate and long-term ade-
quately powered safety studies would be required.
In the larger scale contraceptive clinical trials using testos-
terone enanthate 200 mg every week, which is a supra-
physiological dose, the reported common adverse events in-
clude pain at injection site, acne, weight gain, fatigue, and
mood changes including aggressiveness leading to discontin-
uation in 5.5, 3.3, 0.7, 0.3, and 1.4 % of men, respectively.
Increased or decreased libido and disturbed sleep occurred in a
small number of subjects [38]. In the more recent contracep-
tive clinical trials using testosterone undecanoate (1000 mg
loading and then 500 mg every week) in over 1000 men, the
most common reported side effects were pain at site of injec-
tion (3.9 %), acne (7.4 %), coughing after injection (2.1 %),
and mood or behavior changes (0.8 %) [28••] (Table 2).
There are few clinical trials utilizing combined testosterone
plus a progestin with large number of subjects. When testos-
t e rone implan t s were admin i s t e r ed wi th depo t
medroxyprogesterone acetate, discontinuations were due to
mainly to problems of implants (extrusion, pain, androgen
deficiency due to inadequate testosterone delivery by im-
plants, mood fluctuation, or study-unrelated personal reasons)
[19]. In the most recent contraceptive efficacy study where
testosterone undecanoate 1000 mg was combined with
norethisterone enanthate 200 mg every 8 weeks, there were
adverse events in the 320 participants including the following:
acne, injection site pain, increased or decreased libido, mood
changes including mood swings and depression, aggression
and hostility, and muscle and skeletal pain. One center report-
ed many of the adverse events. This study was stopped pre-
maturely because of these adverse events [29•]. In these stud-
ies, changes in sexual function or mood were not prospective-
ly monitored at the sites, and there was no placebo group. In
studies where sexual function and mood were monitored pro-
spectively by a diary [39], no significant negative changes in
sexual function were found [40, 41•].
In the placebo-controlled randomized clinical trial using
injectable testosterone decanoate and etonogestrel implants
which were highly effective in suppressing spermatogenesis,
adverse events that were reported to occur more frequently in
the active treatment groups include acne, increase in body
TE testosterone enanthate, TU testosterone undecanoate, DMPA depot medroxyprogesterone acetate, NET-EN norethisterone enanthate
a Only adverse events leading to discontinuations reported (italics)
b Cough after injections in 2.1 %; facial swelling/rash 0.8 %
c Two serious adverse events: myotonic dystrophy during recovery phase and multiple congenital malformations (Vater Anomalad) in one twin
conceived during recovery phase. Both considered not related
d Symptoms of hypogonadism (lethargy and sexual dysfunction) occurred in men duringmonth 5 or 6 after T implants because of inadequate testosterone
release from the pellets after 4 months. This necessitated a protocol amendment
e Night sweating was reported in 27 % of men in the active group versus 8 % in the placebo group
fMost of the adverse events are mild or moderate, and many occurred in one center: acne (90 % mild), mood changes (includes 16.9 % emotional
changes, 97 % mild; 4.7 % mood swings; 84 % mild; and 2.8 % depression, five subjects had moderate and two subjects had severe depressive mood/
depression), injection site pain (93 % mild), libido changes (mainly increase; 88 % mild), and behavior changes (83 % mild)
gMood changes include emotional disorder, mood swings, altered mood, and depression
h Libido changes include increase or decrease libido
i Behavior changes include aggression or hostility
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Table 2 Adverse events reported in larger scale male contraceptive clinical trials (over 50 men per group)
Clinical trial Adverse events (% of enrolled subjects)
N Pain/problems
with injection/implant








TE [13] 271 7.5 29.5 4.4 1.5 4.4 2.6 8.1
TE [14]a 399 5.3 2.0 0.5 1.0 0.8 0.8 0
TU 2003 [27] 308 + 6.8 + 0 + 0 0
TU 2009 [28••]b 1045 3.9 7.4 + 0.8 + ? 0
Testosterone + Progestin
T implants DMPA [19]a,c 55 10.9 ? + 1.2 +d ? +d
TU+ Etonogestrel implants [42•]e Active 297 0.6 26 24 19 13 ? +
Placebo 52 2 10 10 10 0 ? ?
TU+NET-EN [29•]f 320 23.1 45.9 3.8 24.4 42.2 5.7 1.6
weight, libido change, mood changes, and night sweating
[42•] (Table 2). There is no uniform requirement of reporting
or coding of adverse events in these contraceptive studies, as
the earlier studies reported adverse events leading to discon-
tinuation, whereas the more current reports contained all ad-
verse events.
Laboratory tests to evaluate safety outcomes showed no
significant changes in renal or liver function. As anticipated
with testosterone treatment, significant increases in hematocrit
and hemoglobin are observed in most studies, but discontinu-
ation due to increases in red cell indices is infrequent. High-
density lipoprotein cholesterol levels are also decreased by
testosterone or testosterone plus progestin, but the clinical
significance of small decreases in high-density lipoprotein
cholesterol is not known because of the complexities of lipo-
protein metabolism and the relationship with risk of cardio-
vascular disease [43, 44].
Factors Affecting Suppression of Spermatogenesis
and Reversibility of Hormonal Male Contraception
In an integrated analysis where semen analyses and clinical
data were available from 1549 healthy male volunteers who
participated in many hormonal male contraception clinical
trials, using androgens or androgens plus progestins showed
that addition of a progestin increased the rate and extent of
suppression. In response to male hormonal contraceptive
agents, non-Asian men suppressed spermatogenesis faster ini-
tially, but eventually, they achieved a less complete suppres-
sion of sperm output [45•]. This study confirmed the earlier
reports that Asian men had more complete suppression of
sperm production than non-Asian men [13, 14]. The reason
for this difference is not known, but several mechanisms have
been proposed. There are differences in testicular
histomorphology and testosterone metabolism between East-
Asian and Caucasian men. However, whether this contributes
significantly to varying degrees of sperm suppression in re-
sponse to exogenous hormonal male contraception is not clear
[46]. Because of these differences between Asian and non-
Asian men, the path of male hormonal contraceptive develop-
ment has focused on androgens plus progestins.
Male hormonal agents are frequently used in female con-
traception, known to suppress gonadotropins, and reversibility
has been assumed. The same integrated analysis examined
whether all men recovered from male hormonal contraceptive
agents that suppressed sperm output to very low regions. The
study showed that the median time to recovery to 10 million/
ml was 3 months and to 20 million/ml was 3.4 months which
is the anticipated time to recovery. These sperm concentra-
tions are compatible with male fertility. The probability of
recovery to 20 million with 12 months is 90 and 100 % within
24 months. The recovery rates were slower with longer
duration of treatment, use of longer acting hormonal prepara-
tions, and non-Asian ethnicity. The recovery rates were higher
with older age, men who suppressed spermatogenesis faster,
higher baseline sperm concentration, and lower baseline se-
rum luteinizing hormone, but these effect sizes were very
small [47••, 48]. The conclusion from this study was that all
men would recover after hormonal male contraception indi-
cating that efforts to develop this reversible and efficacious
method of contraception should continue.
Newer Agents Used for Hormonal Male
Contraception
The focus of hormonal male contraception development in
recent years has been the development of novel androgens
that may be more potent than testosterone in the suppression
of gonadotropins and with fewer potential side effects. 7-
Alpha-methyl-19-nortestosterone (MENT) cannot be 5-alpha
reduced to dihydrotestosterone like steroids and may have less
stimulating effects on the prostate gland. In rats, MENT is ten
times more potent than testosterone in the muscle and only
four times more potent in the prostate gland suggesting less
simulating effects on the prostate compared to testosterone
[49]. This was confirmed in monkeys [50]. Initial studies
using MENT as an implant in men showed very effective
suppression of spermatogenesis with four MENT implants
(releasing a total of 1600 mcg/day MENT) [51]. MENT im-
plants are under development to optimize the delivery rate as a
1-year implant by the Population Council [52].
Another androgen, dimethandrolone (DMA, 7-alpha,11-
beta-dimethyl-19-nortestosterone) undecanoate, is being de-
veloped as an oral preparation as well as an intramuscular
injection. In the body, DMA undecanoate (DMAU) is con-
verted to DMAwhich is the active entity. In in vitro studies,
DMA showed dose-dependent androgenic and progestational
activities. The dual activities on the androgen and progester-
one receptors may create a single agent capable of suppressing
spermatogenesis while maintaining androgenic activity in
men [53]. DMAU has antifertility effects in male rabbits
[54]. A single-dose escalation study in healthy male volun-
teers showed that DMAU appeared to be safe and well-toler-
ated. DMAU has to be administered with a fatty meal to en-
hance absorption from the gastrointestinal tract. After admin-
istration of a single dose of DMAU powder (at a dose
>200 mg/day), significant suppression of serum gonadotro-
pins and testosterone occurred which had not been reported
with other hormonal agents [55]. Repeat daily dosing of
DMAU over 28 days is currently in progress where the goals
are to study safety and tolerability as well as the extent of
suppression of gonadotropins. It is also being formulated as
an injection by the National Institute of Child Health and
Human Development (NICHD), National Institutes of
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Health, USA, for hormonal male contraception studies.
NICHD is also developing levonorgestrel butanoate as a
long-acting progestin injection for male and female
contraception.
Nestorone (16-methylene-17alpha-acetoxy-19-norpregn-
4-ene-3,20-dione) is a potent progestin that has minimal an-
drogen or estrogen activity. The Population Council is devel-
oping nestorone for both female and male contraception [52,
56, 57]. Nestorone applied transdermally has been used in
combination with testosterone gel for hormonal contraception
clinical trials in men. Nestorone and testosterone gels when
applied on the skin suppressed both gonadotropins (LH and
FSH) to very low levels in healthy male volunteers [58]. In a
6-month study, a combined gel (testosterone 100 mg/day and
nestorone 8 mg/day on skin) suppressed sperm output to <1
million/ml in 89 % of men compared to 23 % of those who
applied testosterone gel alone. There were minimal adverse
effects [41•, 59]. Based on the studies, a contraceptive efficacy
study is planned for 2016 using a combined nestorone and
testosterone gel as a provider independent daily application
on the skin.
Men Will Use Male Contraception and Their
Partners Approve Development of Male
Contraception
Acceptability of male contraception was studied with inter-
views in seven cities in Asia, North and South America, and
Europe that were conducting male hormonal contraceptive
studies supported by the World Health Organization. The
study planned to gauge the male users’ evaluation of the hor-
monal method compared to other male methods and whether
these hormonal methods modify sexual function and behavior
[60]. The study showed that a daily pill or a monthly injectable
might have the highest acceptability; monthly interviews ap-
peared to be useful in assessing any sexual dysfunction asso-
ciated with the new method. Other studies of men participat-
ing in clinical trials using various nonvalidated questionnaires
showed that in some studies over 61 % of participants found
testosterone undecanoate injectable method excellent or good
[61], while other studies showed that transdermal application
is acceptable in about 56 % of men [62, 63]. In the monthly
injections of testosterone undecanoate clinical trial in China
[27], most participants (male and female), providers, and pol-
icy makers thought that a new hormonal method would be
acceptable if proven to be safe and effective. In the 308 men
who were receiving the injections, 72.3 % thought monthly
injections and semen analyses, and the need to use another
contraceptive method during the period of sperm suppression
were inconveniences that might reduce the acceptability of the
method [64]. Future studies of acceptability of male contra-
ceptive method will require the development of validated
questionnaires. If the surveys are conducted in participants
in male contraceptive trials, the data collected may be biased
and are not reflective of the general population.
Structured interviews using questionnaires in four cities
(Edinburgh, Cape Town, Shanghai, and Hong Kong) in three
countries, UK, South Africa, and China, showed that 44 to
83 % of men would use a male contraceptive pill. A pill was
preferred to an injectable. Acceptability was variable and in-
fluenced by knowledge of other contraceptive methods and
cultural background [65]. In another study that surveyed over
9000 men (18 to 50 years) in nine countries and four conti-
nents showed that in 55 to 81.5 % of couples, both partners
were involved in selecting the method of contraception. From
28.5 to 71.4% ofmen surveyed expressed willingness to use a
newmale method of contraception with wide variation among
different racial and ethnic groups [66•]. In a study in England
(n=380), both men and women had favorable attitudes to a
male contraceptive pill. Women had amore positive attitude to
the new male pill but had less trust that men would use it
effectively. Men in a stable relationship had a more positive
attitude toward a male pill than those in casual relationships
[67]. The attitude of female partners was also studied in 1894
women attending family planning clinics in Edinburgh,
Cape Town, Shanghai, and Hong Kong. Over 90 % of women
in Edinburgh and Cape Town considered a male pill a good
idea, whereas in Hong Kong and Shanghai, the percent were
lower at 71 and 87%, respectively. Only 2% of women would
not trust their partner to use a male pill [68].
These studies in men and women provided evidence that if
a new male contraceptive method is available, over 50 % of
men may try to use it. Couples in stable relationships trust
each other, and the female partner would trust the male taking
a male contraceptive pill.
Challenges to Bring Male Hormonal Methods
to Become Available to Men
Male contraception can fill an unmet need in contraception,
and based on published surveys, this would be acceptable to
many men and their partners. In addition, new male methods
may relieve the contraceptive burden of women. Because the
required visits to the clinic and interviews with physicians or
providers knowledgeable in reproduction may make men
more aware of their reproductive health. Since the 1970s, hor-
monal male contraceptive trials have been conducted in many
parts of the world. Large-scale studies from 1990s and those
from more recent times showed that hormonal contraception
with androgens alone is very efficacious in Asian men and
regimens with androgens and progestins are efficacious in
all men. The possibility of escape from suppression of sperm
production in men by an androgen alone regimen may be
higher than in androgen and progestin combinations. The
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use of two agents for male contraception is more complex as
the bioavailability and pharmacokinetics of the two entities
should be complementary to each other. Mismatching inject-
able testosterone long-acting injections with a slower increase
in serum testosterone level with shorter acting injectable pro-
gestins that have a rapid burst effect may result in inadequate
androgen effects and symptoms of hypogonadism in the pres-
ence of high progestin levels. The current goals of clinical
investigation are to find different combinations of androgens
and progestins that have similar pharmacokinetics with addi-
tive action on suppression of spermatogenesis and minimal
adverse effects. Newer hormonal steroids that have both an-
drogenic and progestational activity are being developed in
addition to DMAU. The selected agents must be safe without
major adverse effects and can be delivered in a user friendly
method, e.g., daily pill or transdermal gels or three monthly or
yearly injections, and if possible without surgical intervention.
The steady delivery of hormonal steroids for male contracep-
tion has been perceived to have less adverse events than those
that provide serum peaks and troughs of the androgen or the
progestin. The goal is to develop a number of male hormonal
contraceptives such as long-acting injectables, implants, pills,
and transdermal gels to meet the preferences of men and their
partners.
The economic aspects of male hormonal contraception
have been studied. Assuming a market size of 10 million
men in the USA and 50 million men worldwide, the market
value of a new male contraceptive method is estimated to be
worth 40 to 200 billion dollars [69]. The NICHD currently
supports the development of novel targets for male contracep-
tion as well as funding to male hormonal contraceptive clini-
cal trials. The Population Council’s contraceptive develop-
ment focuses on Nestorone and MENT.
The pharmaceutical industry has withdrawn support in re-
search and development of contraception. This lack of indus-
try support despite a large potential market is disappointing
but may be due to several concerns including that men will not
use the prescribed contraception method consistently, cost of
male hormonal methods and differential pricing for developed
and developing countries, and potential unknown long term
side effects. Thus, government and academia will need to
collaborate with community advocates to generate interest in
smaller, specialty pharmaceutical companies that are interest-
ed in reproductive health. Advocacy from public interest
groups will also help to push the agenda forward for male
contraceptive development.
Conclusion
Large-scale clinical trials in men proved that when sperm
output is suppressed to a very low level, the contraceptive
efficacy is very high. Androgens plus a progestin will most
likely be the first hormonal contraception method for men.
The matching of a progestin to testosterone may be more
complex, and a balance between the two steroids may be
necessary to produce a viable, safe, and reversible male hor-
monal contraception. Surveys in men and women in the re-
productive age group suggest that many men and women
would accept male hormonal methods as a contraceptive op-
tion. Partnership between government, nongovernment agen-
cies, academia, and industry will identify the best combina-
tions of steroids to bring forward, conduct clinical trials, and
submit reports to regulatory agencies for approval, and ensure
accessibility of these approved agents by all men.
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